All In Biotech

Drug Trial Radar · NCT06932562

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients

Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Dec 23, 2025

Primary completion

Dec 2036

Study completion Dec 2036

Sponsor

Lead sponsor
European Myeloma Network B.V.Research network
Sponsor type
Research network
Collaborators
Regeneron Pharmaceuticals
First posted
Apr 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.

Conditions

  • Multiple Myeloma

Interventions

  • LinvoseltamabDrug

    Administered per the protocol

  • DaratumumabDrug

    Administered per the protocol

  • LenalidomideDrug

    Administered per the protocol

  • DexamethasoneDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal Residual Disease (MRD)Time frame: up to 11 years
  2. MRD negative CR status by BICRTime frame: up to 11 years
  3. Progression Free Survival (PFS) per IMWG criteriaTime frame: up to 11 years
  4. PFS as determined by BICRTime frame: up to 11 years

Locations

59 sites in 18 countries. Site status is shown where the registry gives one.

  • Flinders Medical Centre

    Adelaide, Australia · Recruiting

  • Box Hill Hospital

    Box Hill, Australia · Recruiting

  • Canberra Hospital

    Canberra, Australia · Recruiting

  • Barwon Health, University Hospital Geelong

    Geelong, Australia · Recruiting

  • Austin Hospital

    Heidelberg, Australia · Recruiting

  • Nepean Cancer Centre

    Kingswood, Australia · Recruiting

  • Northern Hospital

    Melbourne, Australia · Recruiting

  • Sunshine Coast Health

    Sunshine Coast, Australia · Recruiting

  • Ordensklinikum Linz

    Linz, Austria · Recruiting

  • Klinik Ottakring

    Vienna, Austria · Recruiting

  • University Hospital Centre Zagreb - Clinic for Internal Medicine

    Zagreb, Croatia · Recruiting

  • Fakultni Nemocnice Hradec Kralove

    Hradec Králové, Czechia · Recruiting

  • University Hospital Olomouc

    Olomouc, Czechia · Recruiting

  • Fakultni Nemocnice Ostrava

    Ostrava, Czechia · Recruiting

  • Fakultni Nemocnice Plzen

    Pilsen, Czechia · Recruiting

  • Aarhus Universitetshospital

    Aarhus, Denmark · Recruiting

  • North Estonia Medical Centre Foundation

    Tallinn, Estonia · Recruiting

  • Tartu University Hospital

    Tartu, Estonia · Recruiting

  • Helsinki University Hospital Comprehensive Cancer Center

    Helsinki, Finland · Recruiting

  • Kuopio University Hospital

    Kuopio, Finland · Recruiting

  • Universitaetsmedizin Greifswald

    Greifswald, Germany · Recruiting

  • Universitaetsklinikum Schleswig-Holstein -Campus Luebeck - Klinik fuer Haematologie und Onkologie

    Lübeck, Germany · Recruiting

  • University Hospital of Würzburg

    Würzburg, Germany · Recruiting

  • University Hospital of Alexandroupolis

    Alexandroupoli, Greece · Recruiting

  • Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens

    Athens, Greece · Recruiting

  • Evaggelismos Hospital

    Athens, Greece · Recruiting

  • Theagenion Cancer Hospital

    Thessaloniki, Greece · Recruiting

  • Cork University Hospital

    Cork, Ireland · Recruiting

  • Beaumont Hospital

    Dublin, Ireland · Recruiting

  • University Hospital Limerick - Department of Haematology

    Limerick, Ireland · Recruiting

  • AOU Ospedali Riuniti di Ancona

    Ancona, Italy · Recruiting

  • Azienda Ospedaliera Santa Croce e Carle - Ematologia

    Cuneo, Italy · Recruiting

  • A.O.U. Careggi

    Florence, Italy · Recruiting

  • IRCCS Ospedale Policlinico San Martino

    Genova, Italy · Recruiting

  • Ospedale di Legnano, ASST Ovest Milanese

    Legnano, Italy · Recruiting

  • Meldola-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)

    Meldola, Italy · Recruiting

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy · Recruiting

  • Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda - Oncologia

    Milan, Italy · Recruiting

  • Azienda USL IRCCS Di Reggio Emilia

    Reggio, Italy · Recruiting

  • Ospedale "Infermi" di Rimini

    Rimini, Italy · Recruiting

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.